This segment focuses on the development and commercialization of innovative diagnostic solutions leveraging artificial intelligence, particularly the AI Nose platform. Research and development activities include refining gas sensing technology, developing smell language models, and integrating AI into diagnostic devices. Technologies used encompass advanced semiconductor design, AI algorithms, and cloud-based test management platforms. The primary therapeutic areas addressed are hygiene monitoring, environmental monitoring, and potentially early disease detection through scent analysis. The patient impact lies in improved accuracy, faster results, and enhanced accessibility of diagnostic testing. Ainos aims to establish a competitive advantage through its proprietary AI technology and strategic partnerships. Future opportunities include expanding the AI Nose platform's applications in various industries and healthcare settings. Regulatory and clinical aspects involve obtaining necessary approvals for diagnostic devices and validating the accuracy and reliability of the AI Nose platform. Partnerships with companies like ASE Technology Holding and Kenmec are crucial for manufacturing, distribution, and market penetration.

This segment is dedicated to the research, development, and potential commercialization of low-dose oral interferon alpha formulations, specifically VELDONA. Research and development activities include clinical trials to evaluate the efficacy and safety of VELDONA in various disease indications, including viral infections. The core technology is based on nearly four decades of research on interferon alpha's broad treatment applications. The primary therapeutic areas targeted are infectious diseases, with potential applications in other areas. The patient impact is aimed at providing a safe and effective treatment option with minimal side effects. Market positioning involves differentiating VELDONA from existing treatments through its low-dose formulation and potential for oral administration. Future opportunities include expanding the clinical trial program, seeking regulatory approvals, and exploring partnerships for manufacturing and distribution. Regulatory and clinical aspects involve conducting clinical trials, obtaining necessary approvals from regulatory bodies, and ensuring compliance with all relevant regulations. The company has secured a Taiwan patent for VELDONA, indicating progress in protecting its intellectual property.